X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-18 | KALV | Palleiko Benjamin L | CEO | S - Sale+OE | $9.26 | -14,400 | 266,598 | -5% | -$133,294 | |||||
| D | 2024-11-18 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $9.26 | -7,192 | 89,980 | -7% | -$66,573 | |||||
| D | 2024-11-18 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $9.26 | -8,077 | 94,199 | -8% | -$74,766 | |||||
| D | 2024-09-09 | KALV | Palleiko Benjamin L | CEO | S - Sale+OE | $12.19 | -7,352 | 250,800 | -3% | -$89,622 | |||||
| D | 2024-08-23 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $12.40 | -2,135 | 83,745 | -2% | -$26,474 | |||||
| D | 2024-08-23 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $12.40 | -1,916 | 85,676 | -2% | -$23,758 | |||||
| D | 2024-08-19 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $12.01 | -7,973 | 80,880 | -9% | -$95,782 | |||||
| D | 2024-08-19 | KALV | Palleiko Benjamin L | CEO | S - Sale+OE | $12.01 | -14,215 | 242,527 | -6% | -$170,769 | |||||
| D | 2024-08-19 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $12.01 | -7,102 | 84,467 | -8% | -$85,318 | |||||
| D | 2024-06-07 | KALV | Palleiko Benjamin L | CEO | S - Sale+OE | $11.53 | -7,465 | 224,547 | -3% | -$86,068 | |||||
| D | 2024-05-20 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $11.76 | -8,088 | 72,858 | -10% | -$95,151 | |||||
| D | 2024-05-20 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $11.76 | -13,175 | 70,325 | -16% | -$154,997 | |||||
| D | 2024-05-20 | KALV | Palleiko Benjamin L | CEO | S - Sale+OE | $11.76 | -21,959 | 216,387 | -9% | -$258,337 | |||||
| D | 2024-05-20 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $11.76 | -11,610 | 80,074 | -13% | -$136,586 | |||||
| D | 2024-02-20 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $14.07 | -28,288 | 62,157 | -31% | -$397,929 | |||||
| D | 2024-02-20 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $14.11 | -12,053 | 72,895 | -14% | -$170,124 | |||||
| D | 2024-02-20 | KALV | Palleiko Benjamin L | CFO, CBO | S - Sale+OE | $14.11 | -22,802 | 187,315 | -11% | -$321,846 | |||||
| D | 2024-02-20 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $14.12 | -14,295 | 52,886 | -21% | -$201,774 | |||||
| D | 2024-02-20 | KALV | Crockett Thomas Andrew | CEO | S - Sale+OE | $14.11 | -24,888 | 211,203 | -11% | -$351,289 | |||||
2024-02-14 | KALV | Palleiko Benjamin L | CFO, CBO | S - Sale | $15.01 | -40,855 | 159,088 | -20% | -$613,205 | ||||||
2024-02-14 | KALV | Crockett Thomas Andrew | CEO | S - Sale | $15.01 | -58,356 | 181,676 | -24% | -$875,883 | ||||||
2024-02-14 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale | $15.01 | -28,171 | 71,657 | -28% | -$422,827 | ||||||
2024-02-14 | KALV | Yea Christopher | Chief Development Officer | S - Sale | $15.01 | -39,886 | 66,160 | -38% | -$598,661 | ||||||
| M | 2024-02-06 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $14.62 | +86,048 | 4,824,731 | +2% | +$1,257,829 | |||||
2024-02-01 | KALV | Crockett Thomas Andrew | CEO | S - Sale | $16.22 | -10,000 | 117,532 | -8% | -$162,198 | ||||||
2024-01-30 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $14.47 | +88,099 | 4,738,683 | +2% | +$1,274,793 | ||||||
| M | 2024-01-25 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $14.05 | +91,804 | 4,650,584 | +2% | +$1,289,802 | |||||
| M | 2024-01-22 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.53 | +99,129 | 4,558,780 | +2% | +$1,241,685 | |||||
| M | 2024-01-17 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.55 | +143,605 | 4,459,651 | +3% | +$1,801,602 | |||||
| M | 2024-01-11 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.72 | +26,246 | 4,316,046 | +1% | +$333,779 | |||||
2024-01-11 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale | $13.03 | -22,679 | 39,828 | -36% | -$295,514 | ||||||
| M | 2024-01-08 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.54 | +137,700 | 4,289,800 | +3% | +$1,726,457 | |||||
| M | 2024-01-08 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale | $13.01 | -17,321 | 62,507 | -22% | -$225,300 | |||||
| M | 2024-01-03 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.14 | +59,369 | 4,152,100 | +1% | +$720,543 | |||||
| M | 2023-12-27 | KALV | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $12.46 | +519,017 | 4,092,731 | +15% | +$6,465,650 | |||||
2023-12-27 | KALV | Crockett Thomas Andrew | CEO | S - Sale | $12.02 | -30,000 | 127,532 | -19% | -$360,453 | ||||||
| D | 2023-11-20 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $8.23 | -7,985 | 36,568 | -18% | -$65,711 | |||||
| D | 2023-11-20 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $8.23 | -4,958 | 79,828 | -6% | -$40,801 | |||||
| D | 2023-11-20 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $8.23 | -7,113 | 46,046 | -13% | -$58,535 | |||||
| D | 2023-11-20 | KALV | Palleiko Benjamin L | Pres, CFO, CBO, Sec'y | S - Sale+OE | $8.23 | -13,008 | 112,443 | -10% | -$107,047 | |||||
| D | 2023-11-20 | KALV | Crockett Thomas Andrew | CEO | S - Sale+OE | $8.23 | -14,807 | 157,532 | -9% | -$121,851 | |||||
| D | 2023-09-11 | KALV | Cha Albert | Dir | S - Sale+OE | $10.50 | -18,000 | 0 | -100% | -$189,050 | |||||
| D | 2023-08-18 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $10.73 | -8,020 | 26,023 | -24% | -$86,045 | |||||
| D | 2023-08-18 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $10.73 | -4,976 | 73,289 | -6% | -$53,386 | |||||
| D | 2023-08-18 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $10.73 | -7,142 | 41,662 | -15% | -$76,624 | |||||
| D | 2023-08-18 | KALV | Palleiko Benjamin L | Pres, CFO, CBO, Sec'y | S - Sale+OE | $10.73 | -13,067 | 95,254 | -12% | -$140,192 | |||||
| D | 2023-08-18 | KALV | Crockett Thomas Andrew | CEO | S - Sale+OE | $10.73 | -14,876 | 146,756 | -9% | -$159,602 | |||||
| D | 2023-05-18 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $10.14 | -2,604 | 37,310 | -7% | -$26,416 | |||||
| D | 2023-05-18 | KALV | Palleiko Benjamin L | Pres, CFO, CBO, Sec'y | S - Sale+OE | $10.14 | -4,037 | 78,126 | -5% | -$40,953 | |||||
| D | 2023-05-18 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $10.14 | -1,786 | 66,771 | -3% | -$18,118 | |||||
| D | 2023-05-18 | KALV | Crockett Thomas Andrew | CEO | S - Sale+OE | $10.14 | -5,627 | 128,050 | -4% | -$57,083 | |||||
| D | 2023-05-18 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $10.14 | -2,780 | 13,014 | -18% | -$28,201 | |||||
| D | 2023-02-17 | KALV | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $7.66 | -3,412 | 9,347 | -27% | -$26,136 | |||||
| D | 2023-02-17 | KALV | Feener Edward P. | Chief Scientific Officer | S - Sale+OE | $7.66 | -2,228 | 64,352 | -3% | -$17,066 | |||||
| D | 2023-02-17 | KALV | Yea Christopher | Chief Development Officer | S - Sale+OE | $7.66 | -2,727 | 35,709 | -7% | -$20,889 | |||||
| D | 2023-02-17 | KALV | Palleiko Benjamin L | Pres, CFO, CBO, Sec'y | S - Sale+OE | $7.66 | -4,954 | 72,799 | -6% | -$37,948 | |||||
| D | 2023-02-17 | KALV | Crockett Thomas Andrew | CEO | S - Sale+OE | $7.66 | -6,700 | 120,927 | -5% | -$51,322 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |